Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022
Celldex Therapeutics (NASDAQ:CLDX) announced the acceptance of an abstract detailing the Phase 1b study of barzolvolimab (CDX-0159) for patients with antihistamine refractory chronic spontaneous urticaria (CSU). This late-breaking electronic poster presentation will occur at the EAACI Annual Congress 2022 from July 1-3, 2022. The study aims to evaluate the safety and efficacy of multiple ascending doses in 40 patients who continue to experience symptoms despite antihistamine treatment. Results will include findings from various dosage cohorts.
- Acceptance of a late-breaking abstract for presentation at EAACI 2022 highlights the significance of the study.
- The study targets a specific patient population, indicating a focused approach to treatment.
- Potential for positive clinical outcomes from barzolvolimab may enhance investor interest.
- The company faces risks associated with clinical testing and obtaining regulatory approvals.
- Dependence on the successful outcome of the clinical trials to sustain investor confidence.
HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with antihistamine refractory chronic spontaneous urticaria (CSU), has been accepted as a late-breaking electronic poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022, being held July 1-3, 2022.
Presentation details are below:
Abstract Title: Effects of multiple dose treatment with an anti-KIT antibody, CDX-0159, in chronic spontaneous urticaria
Presenting Author: Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité - Universitätsmedizin in Berlin
Abstract No: 100097
Topic: Dermatology
Date: Pre-recorded poster presentation available on demand from Friday, July 1, 2022 at 00:01 a.m. CET (Thursday, June 30 at 6:01 p.m. EDT)
This study is designed to assess the safety and treatment effects of multiple ascending doses of barzolvolimab in up to 40 patients with chronic spontaneous urticaria who remain symptomatic despite treatment with antihistamines. Results from the 0.5, 1.5 and 3 mg/kg cohorts will be included as part of this presentation.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the effects of the outbreak of COVID-19 on our business and results of operations; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Senior Director, Investor Relations & Corporate Communications
(484) 788-8560
ptill@celldex.com
FAQ
What is the purpose of the Phase 1b study for CDX-0159?
When will the results of the CDX-0159 study be presented?
How many patients are involved in the CDX-0159 study?
What are the expected dosages included in the CDX-0159 study results?
What is the significance of the EAACI Annual Congress for Celldex?
